[A25-99] Mirikizumab (Crohn's disease) - Addendum to Project A25-42
Last updated 04.09.2025
Project no.:
A25-99
Commission:
Commission awarded on 29.07.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Indication:
Adults with moderately to severely active Crohn’s disease
Result of dossier assessment:
- Patients who have had an inadequate response with, lost response to, or were intolerant to conventional therapy: unchanged after addendum: added benefit not proven
- Patients who have had an inadequate response with, lost response to, or were intolerant to a biologic agent (TNFα antagonist or integrin inhibitor or interleukin inhibitor): unchanged after addendum: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
DOI:
https://doi.org/10.60584/A25-99
| Project no. | Title | Status |
|---|---|---|
| A25-42 | Mirikizumab (Crohn’s disease) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2025-09-04 A G-BA decision was published.